Serum Erythropoietin and Aging: A Longitudinal Analysis.
Serum Erythropoietin and Aging: A Longitudinal Analysis.
复制标题
血清促红细胞生成素与衰老：纵向分析。
DOI：
10.1182/blood.v104.11.1628.1628
复制
发表时间：
2004
期刊：
影响因子：
20.3
通讯作者：
D. Longo
中科院分区：
文献类型：
--
作者：
W. Ershler;S. Shan;J. McKelvey;A. Artz;N. Denduluri;Josephine Tecson;D. Taub;L. Brant;L. Ferrucci;D. Longo
关于血清促红细胞生成素（EPO）随年龄增长的预期变化存在相互矛盾的数据，主要是因为以前的报告是基于对不同人群的横断面分析。为了研究血清EPO随年龄的变化，我们回顾了巴尔的摩老龄化纵向研究（BLSA）中143名参与者的临床病史、血液学参数和血清EPO水平，这些参与者每隔1 - 2年进行8 - 30年的研究。在第一次就诊时没有人患有贫血（根据WHO标准：女性<12 g/dL;或男性<13 g/dL），但在评估期间有10人（7%）出现贫血。另外20名个体（14%）的血红蛋白下降1.5 g/dL或以上，持续至少两次访视，出于本分析的目的，也被认为是贫血。EPO水平随着年龄的增长而显著上升，对于那些没有相关糖尿病或高血压的人来说，上升的斜率更大。发生贫血但没有高血压或糖尿病的受试者EPO随时间的上升斜率最大。相比之下，那些在BLSA随访期间患有或发展为高血压或糖尿病的患者，其初始EPO水平显着较高，并且随着时间的推移EPO斜率降低。随着年龄的增长，血清EPO的增加可能是对RBC周转率增加或红细胞前体EPO抵抗力增加的补偿。我们怀疑，对于非常高龄的患者，或肾功能受损的患者（例如，糖尿病或高血压），代偿机制变得不足。
! [图][1]
图
! [图][1]
图
[1]：待定：是
There are conflicting data regarding expected changes in serum erythropoietin (EPO) with advancing age, primarily because prior reports have been based upon cross-sectional analyses of diverse populations. To examine changes in serum EPO with age, we reviewed the clinical history, hematological parameters and serum EPO levels of 143 participants in the Baltimore Longitudinal Study on Aging (BLSA) who were studied at 1 – 2 year intervals for eight to thirty years. None had anemia at the time of the first visit (by WHO criteria: <12g/dL for women; or <13 g/dL for men) but it developed in 10 (7%) over the period of evaluation. An additional 20 individuals (14%) had a fall in hemoglobin of 1.5 g/dL or more, sustained over at least two visits, and for the purpose of this analysis were also considered anemic. EPO levels rose significantly with age for the group as a whole, and the slope of the rise was found to be greater for those who did not have associated diabetes or hypertension. Subjects who developed anemia but did not have hypertension or diabetes had the greatest slope in EPO rise over time. In contrast, those who had, or developed hypertension or diabetes during the period of follow-up within the BLSA, had significantly higher initial EPO levels and a reduced EPO slope over time. The increase in serum EPO with aging may be compensating for increased RBC turnover or increased EPO resistance of red cell precursors. We suspect that with very advanced age, or in those with compromised renal function (e.g., diabetes or hypertension), the compensatory mechanism becomes inadequate.
![Figure][1]
Figure
![Figure][1]
Figure
[1]: pending:yes